Growth-hormone and endocrine research is not one evidence category. A releasing-hormone analogue, a receptor agonist, recombinant human growth hormone, a modified growth-factor analogue, a gonadotropin, and a mixed hormone preparation can all appear in the same broad search results while differing in identity, study design, measurement, and regulatory status.
This hub explains those research topics without treating them as interchangeable. It is designed to help readers ask what exact material was studied, which part of an endocrine pathway was measured, whether the evidence came from cells, animals, healthy volunteers, or a defined patient population, and where the conclusion stops.
This page is educational. It does not provide medical advice, treatment recommendations, dosing, preparation, administration, reconstitution, or directions for human or veterinary use. It does not authenticate a Serum Research catalog material.
Start with identity, not the pathway diagram
Two materials can influence the same endocrine pathway without being the same molecule. FDA’s December 2024 CJC-1295 briefing distinguishes two active moieties, with DAC and without DAC, and five free-base or salt substances. This is a scientific advisory-committee briefing, not a final regulatory determination.[1]
Healthy-adult studies of the DAC construct measured pharmacokinetics and circulating growth hormone and IGF-I.[1,2] Those findings do not establish patient-centered benefit or evidence for the no-DAC active moiety. The public human reports do not resolve every salt-form detail.[1]
A UNII or synonym can help locate an identity record, but FDA explicitly warns that UNII availability does not imply regulatory review or approval.[10,13,16] A shared receptor or hormone response likewise does not authenticate a catalog lot. FDA approval concerns the drug and its proposed labeling.[9] Our peptide structural-identity guide explains why sequence and modification details matter; the approved-drug versus research-material guide explains the finished-product boundary.
Growth-hormone-releasing-hormone analogues
CJC-1295 with DAC
DAC refers to an albumin-binding structural design. Its healthy-adult exposure and hormone findings must remain attached to that construct.[1,2] Separately, ClinicalTrials.gov lists the phase 2 HIV-associated visceral-obesity study NCT00267527 as terminated, with no posted results. That old registry record, last updated October 16, 2006, names only “CJC 1295”; it does not resolve the intervention’s exact form or supply a clinical-effect estimate.[18]
CJC-1295 without DAC
CJC-1295 without DAC is a different active moiety. Its free base and acetate are also distinct substances; a shared shorthand name does not settle either distinction.[1] See the free-base, salt, and counterion guide for how these fields affect evidence matching.
Tesamorelin
The March 2025 EGRIFTA WR label concerns a named tesamorelin finished drug for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. It is not indicated for weight-loss management, and long-term cardiovascular safety has not been established. The label expressly says EGRIFTA WR and EGRIFTA SV are not substitutable.[4] The FDA application history checked for this review lists the March 25, 2025 supplement and label; these product-specific facts do not approve an unrelated tesamorelin material.[20]
Growth-hormone secretagogues
Ipamorelin
The randomized phase 2 postoperative-ileus study enrolled 117 people and analyzed 114. Its key published time-to-first-tolerated-meal comparison was not statistically significant; the paper also reports no significant secondary efficacy differences.[3] This is not proof of equivalence or of no possible effect. The published ipamorelin postoperative-ileus study summary explains the result, harms, participant accounting, and unavailable full-methods material. It does not validate a catalog preparation.
Hexarelin / examorelin
FDA’s substance record uses examorelin as the preferred name and lists hexarelin as a synonym.[10] Primary research includes receptor work[11] and a double-blind, placebo-controlled physiology study in 12 men.[12] A short-term hormone response is not proof of growth, body-composition change, recovery, or durable clinical benefit.
Downstream hormones and growth factors
Somatropin
Somatropin is recombinant human growth hormone, not a releasing-hormone analogue or a secretagogue. The GENOTROPIN label describes a 191-residue protein produced using recombinant DNA technology in E. coli, with the amino-acid sequence of pituitary human growth hormone.[7] Its named formulation, presentation, licensed status, and clinical evidence do not authenticate an unspecified “HGH” material.
IGF-1 LR3
FDA’s substance record identifies IGF-1 LR3 as Long-(Arg3)insulin-like growth factor-I.[13] Primary characterization describes an N-terminal extension and Arg3 substitution, with activity dependent on the laboratory model.[14] A rat lactation study found that the tested IGF-I analogues, including Long R3 IGF-I, did not restart milk production under its conditions.[15]
This modified analogue is not mecasermin: the INCRELEX label describes mecasermin as recombinant 70-residue human IGF-I with the endogenous sequence.[21] Evidence for either substance cannot establish that the other, or a catalog material, is the same finished drug.
Reproductive-endocrine hormones
Kisspeptin-10 versus kisspeptin-54
FDA maintains a specific substance record for kisspeptin-10,[16] while the primary identification paper describes a 54-residue human peptide.[17] A catalog label that says only “kisspeptin” does not reveal whether the material is KP-10, KP-54, or another fragment.
hCG and choriogonadotropin alfa
PREGNYL’s label describes chorionic gonadotropin obtained from the urine of pregnant people. OVIDREL’s label describes recombinant choriogonadotropin alfa produced in Chinese hamster ovary cells and discusses glycoform characteristics and biological-activity calibration.[5] The broad name hCG does not specify which source, preparation, assay, or finished product is meant. That distinction is not a claim that the products have no comparable properties.
hMG / menotropins
Menotropins are an activity-standardized preparation, not one discrete peptide sequence. The MENOPUR label separately assigns 75 IU of follicle-stimulating-hormone activity and 75 IU of luteinizing-hormone activity, measured with different bioassays.[6] These are two activity assignments, not a combined universal 150 IU or an amount in milligrams. The mass, concentration, and International Units guide explains why the reference and assay must remain attached to the unit.
Regulatory and safety context
At the review date, FDA’s compounding-risk page lists CJC-1295 under nominated-but-withdrawn substances and describes limited clinical data, immunogenicity and characterization concerns, and serious events including increased heart rate and systemic vasodilatory reactions. Its CJC entry does not distinguish DAC from no-DAC.[19]
The same page lists ipamorelin acetate in 503B Category 2 and kisspeptin-10 in 503A Category 2, with substance- and route-specific safety concerns. It also discusses withdrawn nominations separately.[19] These are not interchangeable legal categories, product approvals, or proof of safety. A historical briefing, registry entry, or UNII must not be substituted for a current product/application check. Our trial and FDA status-checking guide explains that process.
How evidence is separated on this hub
| Evidence type | What it can support | What it cannot establish by itself |
|---|---|---|
| Receptor, biochemical, cell, or tissue | Activity in a defined experimental system | A patient benefit, clinical safety, or catalog identity |
| Animal | A finding in the named species and model | The same result in people |
| Human physiology or pharmacokinetics | A measured hormone, exposure, or short-term response under a protocol | Durable clinical effectiveness |
| Controlled human trial | A comparison for the exact intervention, population, endpoints, and duration | Results for another analogue, form, mixture, or product |
| FDA label or application | Status and claims for the named finished product | Approval of an unrelated material sharing an ingredient name |
NIH describes translation as an iterative spectrum in which basic, preclinical, and clinical stages inform one another.[8] The stages do not create an automatic ladder from receptor activity to a human outcome. Our cell, animal, and human evidence guide expands these boundaries.
Boundaries this hub keeps visible
- CJC-1295 with DAC is not CJC-1295 without DAC.
- A free base, acetate, and trifluoroacetate are distinct chemical entities.
- Tesamorelin is not CJC-1295.
- Somatropin is not a growth-hormone secretagogue.
- IGF-1 LR3 is not mecasermin.
- Kisspeptin-10 is not kisspeptin-54.
- Urinary-derived hCG is not recombinant choriogonadotropin alfa.
- Biological activity in IU is not mass in milligrams.
- Evidence for a named FDA-approved finished product does not authenticate a catalog material.
Published compound records
Frequently asked questions
Are all growth-hormone-related peptides interchangeable?
No. They can differ in sequence, modification, target, duration, form, formulation, and evidence base. Even CJC-1295 with DAC and without DAC are different active moieties.
Does a rise in a hormone prove a health benefit?
No. A hormone measurement alone does not establish a patient-centered benefit. The interpretation depends on the intervention, population, comparator, duration, and whether the endpoint is validated for the particular claim. See surrogate endpoints versus clinical outcomes.
Is tesamorelin FDA approved?
A named tesamorelin finished drug has product-specific FDA approval under its controlling label. That does not approve every material called tesamorelin or establish equivalence to a catalog item.
Are hCG and hMG amounts measured the same way?
No. These biological preparations use product- and assay-specific activity units. Activity units and mass answer different measurement questions.
Does an approved somatropin product validate a bulk HGH kit?
No. Approval belongs to the named finished product, application, manufacturing controls, presentation, and label.
Does this hub recommend a protocol or combination?
No. It organizes evidence records and deliberately provides no use, preparation, administration, dosing, or combination guidance.
Primary and official sources
Teichman et al., CJC-1295 healthy-adult studies, PMID 16352683
Beck et al., randomized ipamorelin phase 2 study, PMID 25331030
Pong et al., growth-hormone secretagogue receptor study, PMID 8838145
Imbimbo et al., double-blind hexarelin physiology study, PMID 7957536
Francis et al., recombinant Long-(Arg3)IGF-I characterization, PMID 1378742
Negative rat lactation-model study of IGF-I analogues, PMID 7513341
Ohtaki et al., primary identification of human kisspeptin-54, PMID 11385580
FDA, compounding substances with potential significant safety risks
Review and corrections
Sources checked September 2, 2026 (America/Edmonton), corresponding to September 3, 2026 (UTC). Serum Research is responsible for this editorial summary. No independent scientific, clinical, statistical, analytical, or regulatory review is claimed. This is a selected-source educational guide, not a systematic review, medical advice, or a finding of product quality, safety, or equivalence. Primary-paper summaries use the cited abstracts and official reviews; the linked study summary states its fuller access limitations.
Read how we review evidence or return to the Research Library. Report a source or factual concern through our contact page.